Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 29.76 CNY -0.6% Market Closed
Market Cap: 22.9B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock under the Base Case scenario is 48.46 CNY. Compared to the current market price of 29.76 CNY, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
48.46 CNY
Undervaluation 39%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.9
P/S
P/S
Price to Sales
2.9
vs History
44
vs Industry
37
Median 3Y
3.1
Median 5Y
2.8
Industry
2.4
Forward
2.6
More Details
24.6
P/E
P/E
Price to Earnings
24.6
vs History
50
vs Industry
17
Median 3Y
26
Median 5Y
24.8
Industry
20.6
Forward
19.5
More Details
19.5
P/OCF
P/OCF
Price to OCF
19.5
vs History
82
vs Industry
20
Median 3Y
33
Median 5Y
23.5
Industry
15.5
More Details
14.8
P/FCFE
P/FCFE
Price to FCFE
14.8
vs History
98
vs Industry
24
Median 3Y
26.6
Median 5Y
28.8
Industry
23
More Details
3.6
P/B
P/B
Price to Book Value
3.6
vs History
38
vs Industry
19
Median 3Y
3.7
Median 5Y
3.3
Industry
1.9
More Details
2.9
EV/S
EV/S
Enterprise Value to Sales
2.9
vs History
38
vs Industry
36
Median 3Y
2.9
Median 5Y
2.6
Industry
2.5
Forward
2.6
More Details
6.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.3
vs History
52
vs Industry
31
Median 3Y
6.6
Median 5Y
6.4
Industry
4.9
More Details
29.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
29.1
vs History
46
vs Industry
11
Median 3Y
30.4
Median 5Y
28.4
Industry
12.6
Forward
15.2
More Details
29.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
29.1
vs History
46
vs Industry
14
Median 3Y
30.4
Median 5Y
28.4
Industry
15.7
Forward
21.2
More Details
19.6
EV/OCF
EV/OCF
Enterprise Value to OCF
19.6
vs History
68
vs Industry
21
Median 3Y
30.6
Median 5Y
21.9
Industry
14
More Details
22.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.2
vs History
92
vs Industry
20
Median 3Y
39.2
Median 5Y
30.6
Industry
17.7
More Details
2.6
EV/IC
EV/IC
Enterprise Value to IC
2.6
vs History
66
vs Industry
27
Median 3Y
3
Median 5Y
2.8
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
22.9B CNY 2.9 24.6 29.1 29.1
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Average P/E: 26
24.6
18%
1.4
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Average EV/EBIT: 1 700.2
29.1
27%
1.1
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 249,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.